PowerPoint Presentation

Company Snapshot

NeuroTech Solutions Ltd (NTS) is a leading provider of innovative cloud-based software technologies focused on assessment, monitoring and improvement of human cognition and behavior, with a particular emphasis on attention.

Established Market Presence for ADHD product: MOXO Continuous Performance Test

EU, Americas, Asia, S. Africa

CE approved

National/Regional distributors

Installed Base: 400 centers, 88,000+ tests since launch

>20% sales growth y-y

Additional new markets in process

Dynamic development and clinical research portfolio

2

Karina

2

ADHD Market Drivers

24/7 connectivity, urbanization

Increased awareness, rising social expectations

Shifting diagnostic guidelines

UK Potential Market

According to NICE guidance1, the prevalence of ADHD is 5% of school-aged children. Also according to NICE,

ADHD is currently underdiagnosed in the UK.

1% of school-aged children meet the diagnostic criteria for severe combined type ADHD and should receive treatment (this equates to approximately 100,000 children in the UK). However only 70,000 children are currently receiving medication for their ADHD.

Over half (54%) of the child and adolescent psychiatrists and community pediatricians recently surveyed also stated that ADHD is currently underdiagnosed in the UK

1 National Institute for Clinical Excellence. Technology Appraisal Guidance No. 13. Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention-Deficit/Hyperactivity Disorder (ADHD) in childhood. October 2000

3

UK Survey Findings3: the potential impact of undiagnosed and untreated ADHD

ADHD was rated as having as great an impact on a childs development as depression, Tourettes Syndrome, anxiety or dyslexia. 80% of specialists surveyed rated ADHD as having the greatest or second greatest impact of these conditions on a childs development

98% of those surveyed believed undiagnosed ADHD has a serious impact on a childs academic progress and they are more likely to drop out of school several years earlier than their peers

Over 90% said that undiagnosed and untreated ADHD:

Has a serious impact on a childs relationships with their parents, siblings and peers

Can result in children feeling excluded from their peers, impacting their ability to make friends and leading to very low self-esteem due to their exclusion

Can lead to a variety of social problems, such as difficulties finding and keeping a job and criminal behavior (such as stealing, shoplifting and vandalism)

4

3 Synergy Healthcare Research: ADHD in the UK Today. Survey of 50 child and adolescent psychiatrists and 75 paediatricians, July 2003

4

5

ADHD Assessment Tools

DSM-IV or ICD-10

Questionnaires completed by the specialist, parents and teachers e.g. Conners Teacher and Parent

Rating Scales

Tests which measure the length and type of mental process (psychometric tests and profiles)

Tests of attention and persistence e.g. Continuous Performance Test (CPT)

Challenging diagnostic environment:

ADHD symptoms overlap with those of other disorders

6

Other psychiatric/behavioral disorder

Stimulant Addiction/Enhancement

ADHD with Comorbidity

Pure Attention Disorder

Diagnosis of ADHD can be difficult because other problems (such as autism, Aspergers Syndrome, epilepsy, depression, brain injury or family dysfunction) can result in behavior similar to ADHD.

Perception of over diagnosis and overprescribing

CD, ODD

6

7

Unmet need:

easily-deployed, cost-effective, objective tool

to support clinical diagnosis and research

Next Generation Solution: MOXO d-CPT Test

Accessible

8

Expensive

Limited

Affordable

NEBA

Quotient

AULA

IVA+

QBtest

Conners CPT III

GDS

T.O.V.A

9

MOXO:

Streamlined,

Effective Assessment of Attention

Low Overhead

Patient-Centric

Objective

Innovative

Universal

Secure

Cloud-based, no specialized HW

Accessible from anywhere

Automated, immediate results

Contemporary reference group collected across four continents

Novel multimodal distractor- approach simulates real-life, sensory and emotional features

No language/number confounds

Pediatric and teen/adult versions

HIPAA and EU privacy compliant

10

Demonstration of MOXO Stimuli

Pediatric Version

Click on graphic to view demonstration

Demonstration of MOXO Stimuli

Teens/Adults Version

Karina

Not pediatric version with age-appropriate stimuli/distractors

11

Test Results Reports

Patient Profile

Comparison of individual performance to norm group.

Norm criteria: age and gender

Indices: Attention, Timing, Hyperactivity and Impulsiveness

Scoring: Calculated for each index and categorized by performance level

Includes severity measure for aberrant scores

Performance Graph

Maps performance throughout the test

Baseline

Major/Minor auditory

Major/Minor visual

Combined

Provides distractor impact by index

Example: impulsivity change due to major visual distractors

13

Market Segments

Additional Verticals:

Universities, HR agencies, Driver ExaminationCenters,

A diagnosis of ADHD should only be made by a specialist psychiatrist, pediatrician or other appropriately qualified healthcare professional with training and expertise in the diagnosis of ADHD (NICE Guidelines)

Patient: Female | 14Y

Use Case: NeurologistPharmacotherapy Assessment & Monitoring

Unmedicated

MPH 10 mg

MPH 36 mg

MPH 54 mg

Clinician tracked patient status titration process for selection of optimal drug dose

14

Use Case: Psychologist

Monitoring Utility of Psychotherapy

Before

After

Female | 14y

Psychologist tracked patient status across therapy sessions to assess effectiveness of approach

j

15

16

MOXO: Supporting Eco-System

MOXO

School system

Health System

Professi-onals

Key Scientific Advisors

Edmund Sonuga-Barke, PhD

Member, World Health Org. workgroup on Future of Psychiatric Diagnosis

Itai Berger, MD

Director, Pediatric Neurology Unit and Neuro-Cognitive Center, Hadassah University Hospital

David Coghill, MD

Reader in Child and Adolescent Psychiatry, University of Dundee, UK Visiting Professor of Child and Adolescent Psychiatry, Ning-Bo University, China

MOXO: business opportunity

18

Need: Growing demand for ADHD diagnosis

The MOXO Solution: objective, accurate, based on modern norms

Significant market presence: Turkey, Poland, S. Africa, Mexico, Spain, Israel and additional markets underway

Market acceptance: consistently used by hospitals, universities, large clinics around the globe

ROI: low overhead, streamlined cloud-base service

Clinician-centric tools: coherent results report, developmental report, comparative report (for longitude monitoring), large data base analytics, GCP compliant clinical system

www.neurotech-solutions.com I www.moxo-adhdtest.com